141 results on '"Kelly, Ronan J."'
Search Results
102. 484 - Serial Endoscopic Evaluation of Esophageal Disease in A Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development
103. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
104. Systemic Treatment of Advanced Thymic Malignancies
105. New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer
106. Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?
107. New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
108. Glial Activation in AβPP/PS1 Mice is Associated with Infiltration of IFNγ-Producing Cells
109. Genomic Alterations in Advanced Esophageal Cancer May Lead to Subtype‐Specific Therapies
110. Thymoma Versus Thymic Carcinoma: Differences in Biology Impacting Treatment
111. Vaccines for lung cancer
112. HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted
113. Reducing the Cost of Cancer Care: How to Bend the Curve Downward
114. A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
115. A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1® in Combination With Paclitaxel in Solid Tumors
116. Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
117. Thymic Malignancies: From Clinical Management to Targeted Therapies
118. A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
119. Lung Cancer Vaccines
120. Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
121. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
122. Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
123. A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
124. Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
125. Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity
126. Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
127. The role of talactoferrin alfa in the treatment of non-small cell lung cancer
128. Thymoma-Associated Paraneoplastic Polymyositis
129. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine
130. Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
131. Small-molecule inhibitors of the human epidermal receptor family
132. Transforming growth factor-beta: A target for cancer therapy
133. Renal toxicity of targeted therapies
134. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
135. Transforming growth factor-beta: A target for cancer therapy.
136. Immune-related encephalitis after immune checkpoint inhibitor therapy.
137. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
138. The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling.
139. State of the art management of metastatic gastroesophageal cancer.
140. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice.
141. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.